Provided herein are fermented beverages comprising symbiotic microbial communities, and methods of production thereof.

Described are microorganisms which are able to inhibit the formation of foot malodor by skin microorganisms. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

The present invention relates to a microorganism for drug delivery, which has been transformed with a gene construct comprising a therapeutically active peptide, which can be delivered safely into the intestines through oral administration, and which can express and secrete the therapeutic peptide in the gastrointestinal tract, and also relates to a pharmaceutical composition for prevention or treatment of gastrointestinal disease, which includes the same. The present invention is directed to a lactic acid bacteria drug delivery system capable of overexpressing and secreting a lactic acid bacteria-derived anticancer protein, which is developed by introducing the anticancer protein into a lactic acid bacteria expression and secretion system. It is expected that the lactic acid bacteria drug delivery system will be widely used as a natural protein therapeutic agent against gastrointestinal disease in the medical field.

The present invention relates to a method for simply diagnosing the progress of disease condition of a Parkinson's disease patient. Provided are a method for determining Parkinson's disease using the number of one or more intestinal bacteria selected from the group consisting of Bifidobacterium, Bacteroides fragilis group, Lactobacillus brevis, and Lactobacillus plantarum subgroup and/or the total number of intestinal bacteria as a marker, and a method for determining Parkinson's disease using the blood LPS level and/or the blood LBP level of a Parkinson's disease patient as an indicator.

An object is to provide lactic acid bacteria that can be applicable to feed, fertilizers, live bacterial preparations, probiotics, etc. The lactic acid bacteria are identified and deposited under the accession numbers of NITE (National Institute of Technology and Evaluation) P-02313, NITE P-02314, NITE P-02490, NITE P-02491, and NITE P-02492. In addition, another object is to provide feed, fertilizers and live bacterial preparations containing the lactic acid bacterium/bacteria of the invention. According to studies, it is confirmed that the lactic acid bacteria are proliferated in animals including human, plants, etc. without being destroyed. According to studies, it is also confirmed that the lactic acid bacteria are proliferated in water, soil, etc. without being destroyed. Therefore, the lactic acid bacteria can be widely applicable in feed, fertilizers, live bacterial preparations, etc.

Isolates strains of gastrointestinal bacteria from wolves are provided for use as probiotics. In some embodiments, the isolated strains are for use as probiotics in canine subjects such as domestic dogs. In some embodiments, the isolated strains may be used to treat or prevent intestinal dysbiosis in the subject. Also provided are compositions comprising at least one isolated strain of wolf probiotic bacteria and related methods for making same.

The present invention disclosure relates to a new probiotic strain of Lactobacillus brevis, isolated from pique and exhibiting anti-cancer properties, as welt as to compositions which contain said strain.

The present invention relates to a microorganism for drug delivery, which has been transformed with a gene construct including a therapeutically active peptide, is delivered safely into the intestines through oral administration, and expresses and secretes a cystatin in the gastrointestinal tract, and also relates to a pharmaceutical composition for prevention or treatment of gastrointestinal disease, which includes the same. The present invention demonstrates the safety and superiority of lactic acid bacteria as a system for delivering a protein-based drug, and thus it is expected the lactic acid bacteria will be widely used as an agent for treatment of gastrointestinal disease in the medical field.

The invention concerns novel Lactobacillus strains and the uses thereof, in particular for preserving foods, animal feedstuff, pharmaceutical compositions and/or cosmetic compositions.

Provided are Saccharomyces cerevisiae SPC-SNU 70-1 (KCTC 12776BP) which is a novel natural Korean yeast isolated from traditional Korean nuruk, and Lactobacillus brevis SPC-SNU 70-2 (KCTC 12777BP), Lactobacillus curvatus SPC-SNU 70-3 (KCTC 12778BP) and Lactobacillus sanfranciscensis SPC-SNU 70-4 (KCTC 12779BP) which are novel natural Korean lactic acid bacteria isolated from traditional Korean nuruk.